🚀 The Future of CGT Manufacturing: Which leading edge technology should we bring in next? 🚀 The cell and gene therapy (CGT) industry is evolving fast, and automation is at the heart of scaling up efficiency, consistency, and patient access. But where should we focus our digitization and automation efforts? 🤔 We're running a quick LinkedIn poll to hear from YOU—our community of CGT professionals, innovators, and problem-solvers. 📊 Which CGT manufacturing process would benefit most from automation? 🔹 Cell washing 🔹 Selection 🔹 Expansion 🔹 Fill/finish 💡 Vote now and share your insights in the comments! What challenges are you seeing in these steps? Have you implemented automation in your workflow? Let's spark a discussion that helps shape the future of CGT manufacturing! ⚙️🔬 📢 Don’t just vote—tag your network! Invite your colleagues, peers, and industry leaders to weigh in. The more voices, the better the insights! Learn more at info@adthera.bio | adthera.bio #cdmo #regenerativemedicine #digitalfirst #celltherapy #immunotherapy #innovation #processdevelopment #continousimprovement #gmp #clinicaltrials #atmp #advancedtherapies #personalizedmedicine #gxp #optimization #automation #bestinclass #rightfirsttime #celltherapymanufacturing #innovation #digital #partnerships #collaboration #networking #digitaltransformation #quailtycontrol #qualityassurance #GMP #simulation #manufacturing #processdevelopment
This content isn’t available here
Access this content and more in the LinkedIn app